- Home
- RYDE vs XRTX Comparison
RYDE vs XRTX Comparison
Compare RYDE & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYDE
- XRTX
- Stock Information
- Founded
- RYDE 2014
- XRTX 2011
- Country
- RYDE Singapore
- XRTX Canada
- Employees
- RYDE N/A
- XRTX N/A
- Industry
- RYDE
- XRTX Pharmaceuticals and Biotechnology
- Sector
- RYDE
- XRTX Health Care
- Exchange
- RYDE NYSE
- XRTX Nasdaq
- Market Cap
- RYDE 5.2M
- XRTX 4.2M
- IPO Year
- RYDE 2024
- XRTX N/A
- Fundamental
- Price
- RYDE $0.27
- XRTX $0.84
- Analyst Decision
- RYDE
- XRTX
- Analyst Count
- RYDE 0
- XRTX 0
- Target Price
- RYDE N/A
- XRTX N/A
- AVG Volume (30 Days)
- RYDE 29.2M
- XRTX 30.3K
- Earning Date
- RYDE 05-02-2025
- XRTX 08-13-2025
- Dividend Yield
- RYDE N/A
- XRTX N/A
- EPS Growth
- RYDE N/A
- XRTX N/A
- EPS
- RYDE N/A
- XRTX N/A
- Revenue
- RYDE $6,557,978.00
- XRTX N/A
- Revenue This Year
- RYDE $21.13
- XRTX N/A
- Revenue Next Year
- RYDE $13.43
- XRTX N/A
- P/E Ratio
- RYDE N/A
- XRTX N/A
- Revenue Growth
- RYDE 3.27
- XRTX N/A
- 52 Week Low
- RYDE $0.16
- XRTX $0.80
- 52 Week High
- RYDE $22.49
- XRTX $2.98
- Technical
- Relative Strength Index (RSI)
- RYDE N/A
- XRTX 39.98
- Support Level
- RYDE N/A
- XRTX $0.80
- Resistance Level
- RYDE N/A
- XRTX $0.88
- Average True Range (ATR)
- RYDE 0.00
- XRTX 0.05
- MACD
- RYDE 0.00
- XRTX -0.00
- Stochastic Oscillator
- RYDE 0.00
- XRTX 24.20
About RYDE RYDE GROUP LTD
Ryde Group Ltd operates a technology platform that provides a range of ride-hailing, carpooling and delivery focused offerings in Singapore. The company operates in twos segments namely Mobility provides on-demand and scheduled carpooling and ride-hailing services, matching riders to its driver partners; and Quick Commerce provides on-demand, scheduled, and multi-stop parcel delivery services.
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.